Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)
Others
Ratios

BioLineRx (BLRX) Income from Continuing Operations (2023 - 2025)

Historic Income from Continuing Operations for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to -$1.9 million.

  • BioLineRx's Income from Continuing Operations rose 4941.52% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.8 million, marking a year-over-year increase of 5208.92%. This contributed to the annual value of -$19.3 million for FY2024, which is 6207.47% up from last year.
  • As of Q3 2025, BioLineRx's Income from Continuing Operations stood at -$1.9 million, which was up 4941.52% from -$2.0 million recorded in Q2 2025.
  • BioLineRx's 5-year Income from Continuing Operations high stood at -$1.9 million for Q3 2025, and its period low was -$17.5 million during Q4 2023.
  • Over the past 3 years, BioLineRx's median Income from Continuing Operations value was -$3.9 million (recorded in 2024), while the average stood at -$6.6 million.
  • As far as peak fluctuations go, BioLineRx's Income from Continuing Operations skyrocketed by 6734.38% in 2024, and later soared by 4503.8% in 2025.
  • Over the past 3 years, BioLineRx's Income from Continuing Operations (Quarter) stood at -$17.5 million in 2023, then soared by 54.75% to -$7.9 million in 2024, then soared by 76.03% to -$1.9 million in 2025.
  • Its last three reported values are -$1.9 million in Q3 2025, -$2.0 million for Q2 2025, and -$2.0 million during Q1 2025.